The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.
Michael Wang, MD, discusses the impact of acalabrutinib in patients with mantle cell lymphoma, the implications of the phase 2 ACE-LY-004 trial, and the challenges faced with treating those who harbor TP53 mutations.
Pirtobrutinib elicited encouraging responses across all dose levels in patients with mantle cell lymphoma and other non-Hodgkin lymphoma who previously received all classes of available therapy, with benefit observed independent of prior therapy received, according to data from the phase 1/2 BRUIN study.
More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.
For patients with mantle cell lymphoma who have progressed after treatment with a BTK inhibitor such as ibrutinib, there is an unmet need for the development of safe and effective targeted therapies to improve otherwise dismal outcomes.
The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.
The addition of venetoclax to lenalidomide and rituximab resulted in a high response rate and encouraging minimal residual disease undetectability in patients with newly diagnosed mantle cell lymphoma—even in those with high-risk features.
Mitchell R. Smith, MD, PhD, discusses the results of the ECOG-ACRIN E1411 trial examining BR-based induction treatment in patients with mantle cell lymphoma and next steps for research.
This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.